Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NYSE:NVS ) Q3 2022 Earnings Conference Call October 25, 2022 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Graham Parry - Bank of America Wimal Kapadia - Bernstein Richard Parkes - BNP Paribas Emmanuel Papadakis - Deutsche Bank Matthew Weston - Credit Suisse Simon Baker - Redburn Richard Wagner - Wolfe Research Stephen Scala - Cowen Kerry Holford - Berenberg Richard Vosser - JPMorgan Emily Field - Barclays Keyur Parekh - Goldman Sachs Mark Purcell - Morgan Stanley Seamus Fernandez - Guggenheim Securities Florent Cespedes - Societe Generale Andrew Baum - Citi Peter Welford - Jefferies Operator Good morning and good afternoon and welcome to the Novartis Q3 2022 Results Release Conference Call and Live Webcast. [Operator Instructions] A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.

Novartis AG (NVS) Q3 2022 Earnings Call Transcript

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

Novartis reported revenues and earnings that were down year over year. Currency rate movements were responsible for that, however, Novartis' underlying performance was pretty solid.

Novartis: Healthy Results

Novartis stock was mostly unmoved Tuesday after the company's earnings beat expectations, but third-quarter sales came up short. The post Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff appeared first on Investor's Business Daily.

Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff

Vanguard Health Care ETF

Most investors, economists, CEOs, and the bond market are confident a recession is coming in 2023. That means potentially another 15% to 20% downside risk for the market. Consumer staples, healthcare, and utilities historically perform the best in recessions, but healthcare is the best performing defensive sector once the new bull market begins.

2 Dividend Blue-Chips Perfect For 2023

Amgen

AstraZeneca

IQVIA Hlds

Johnson & Johnson

Regeneron Pharmaceuticals

Biosimilars are bringing down prescription drug costs without sacrificing quality.

Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?

Novartis earnings and sales fall short of expectations, but backs 2022 view

Ad hoc announcement pursuant to Art. 53 LR

Novartis maintains growth momentum and confirms FY'22 Group guidance

Novartis AG NOVN, +0.47% NVS, +2.05% said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.

Novartis hemoglobinuria trial meets two primary endpoints

Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH study

Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.

What's in Store for Novartis (NVS) This Earnings Season?

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617), a radioligand therapy, in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. “People at this advanced stage of disease have already received many different treatments and have few alternatives left,” said Prof. Karim Fizazi, MD, PhD, VISION trial investigator and Head of Medical Oncology at Gustave Roussy, first European cancer center based in Villejuif, France. “If approved in Europe, Pluvicto® would represent a new type of precision medicine targeting a biomarker broadly expressed in prostate cancer patients4 and provide a therapeutic option with demonstrated potential to improve outcomes1. As a clinician this gives me hope for patients facing a very difficult situation.”

Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer

Paramount Global

Whether you're looking for dividends or growth, Novartis and Paramount Global could be viable options for you.

Got $5,000? These 2 Stocks Are Bargain Buys Right Now

Novartis recently announced encouraging results from its clinical trial of its Prolia biosimilar.

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

AbbVie

Abbott Labs

Acadia Healthcare

Bristol-Myers

Cardinal Health

Cigna

CVS Health

Merck

Novavax

Pfizer

Teladoc

UnitedHealth Group

Health care stocks are traditionally a defensive play for investors in a falling market. It's a rich market with blue chip insurance providers, service providers, pharmaceutical companies, retailers, and tech players.

Health Care Stocks: Reviewing The Best Of The Industry

Roche Holding AG

NVS vs. RHHBY: Which Stock Is the Better Value Option?

NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Novartis (NVS) a Great Value Stock Right Now?

Novartis ( NVS , Financial) has launched some of the most novel therapeutics over the past five years, and yet it sells at just a few dollars above its 52-week low, has a trailing 12-month price-earnings ratio of just 7.50 and pays a dividend that yields 4.37%. Shares of Novartis have lost 11.8% so far this year compared with the industry's decline of 5%.

Novartis's Strategic Plan Brings Many Plusses

Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.

Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs

Novartis AG NOVN, -0.84% on Thursday told investors that the Swiss drug maker plans to adopt a "U.S.-first mindset" in its bid to become a "top-five player" in the U.S. market by 2027. Novartis is one of the world's largest pharmaceutical companies; however in the U.S., it was the tenth largest by revenue in the U.S. in 2021, according to FiercePharma.

Novartis outlines plan to become a 'top-five player' in U.S. pharmaceuticals market

Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.

Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent

CF Industries Holdings

Canadian Natural Resources

Cenovus Energy

Marcus & Millichap

Sociedad Quimica Y Minera De Chile

Investors who have a high exposure to stocks in 2022 probably wish the year would end. Unless they raised their allocation in cash, their losses in the portfolio are mounting.

7 Safe Havens All Investors Should Have Exposure to in 2022

Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world's largest pharmaceutical market.

Novartis to prioritise U.S. market unfazed by drug pricing pushback

Basel, September 22, 2022 — Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management event. The meeting will allow participants to learn more about Novartis journey to unite technology leadership in Research and Development with novel access approaches, helping to alleviate some of society's greatest disease burdens.

Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management event

News for Novartis Stock (NVS)